A pathophysiological effect of a transient receptor potential cation channel, subfamily V, member 3 (TRPV3) on psoriasis, which can be used to develop a drug for preventing or treating psoriasis. The invention further discloses an application of Scutellarein as a TRPV3 inhibitor in preparing a drug for preventing or treating psoriasis. When a drug containing the TRPV3 inhibitor discovered according to the invention or provided by the invention is used for preventing or treating psoriasis, good prevention or treatment effects can be achieved.